NEP Interlong is planning to acquire a portion of Jinbaihui's equity through the issuance of new shares or the acquisition of existing shares.

NEP INTERLONG (08329) announced that the company plans to acquire a portion of the equity of Shenzhen Jinbaihui Biotechnology Co., Ltd. (Jinbaihui) through the issuance of new shares or the acquisition of existing shares, and to conduct related business activities in conjunction with the sales resources of the company's controlling company and the products developed on Jinbaihui's exclusive technology platform. The company hopes that this cooperation can extend the group's industrial chain, expand the market, and cultivate new growth points for the group's future development. If the cooperation is successfully concluded and Jinbaihui's business development goes smoothly, the company will consider further increasing its shareholding. As of the date of this announcement, the company has signed an investment intention letter for the potential investment mentioned above, but has not entered into any legally binding investment agreement. It is reported that Jinbaihui focuses on the field of early diagnosis and screening of tumors, and has a complete industrial chain for the research and development, production, sales of diagnostic reagents and instruments, and third-party medical testing, providing a complete solution in tumor diagnosis with technology, reagents, instruments, and services. Jinbaihui has a miRNA (microRNA) technology platform, as well as the first domestic colorectal cancer detection product based on miRNA technology. At the same time, this product is the first class III colorectal cancer gene detection device product in China. Currently, Jinbaihui has independently developed and authorized more than ten domestic and foreign invention patents, and its detection products for colorectal cancer, gastric cancer, nasopharyngeal cancer have obtained EU CE certification, while detection products for high-incidence cancer such as breast cancer, pancreatic cancer, prostate cancer, bladder cancer, and pan-cancer are still under development.